PACB vs TXG
PACB: Pacific Biosciences provides high-accuracy, long-read genomic sequencing solutions that enable researchers and clinicians to solve complex genetic challenges. TXG: 10x Genomics provides microfluidic and spatial transcriptomics instruments and consumables that enable researchers to analyze individual cells and tissue architecture at previously inaccessible resolution and scale.
Side-by-side fundamentals
| Metric | PACB | TXG | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.38 | $47.05 | |
| Market cap as of 2026-07-23 | $435M | $6.0B | |
| Net margin as of 2026-07-23 | -80.3% | -3.5% | TXG higher |
| Gross margin as of 2026-07-23 | +40.3% | +69.7% | TXG higher |
| Operating margin as of 2026-07-23 | -83.3% | -6.1% | TXG higher |
| ROE as of 2026-07-23 | -488.4% | -2.9% | TXG higher |
| ROA as of 2026-07-23 | -16.1% | -2.2% | TXG higher |
| Debt / equity as of 2026-07-23 | 272.23 | 0.00 | TXG lower |
| Revenue growth (YoY) as of 2026-07-23 | +5.0% | +2.3% | PACB higher |
| Revenue CAGR (3y) SEC XBRL | -6.9% | +7.6% | TXG higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 2.35 | 2.05 | |
| 1-year return as of 2026-07-22 close | -14.8% | +262.2% | TXG higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.